Navigation Links
Endocrinology Panel Examines Interplay Between Diabetes and Cardiovascular Disease in New Report
Date:12/4/2007

SCOTTSDALE, Ariz., Dec. 4 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for T2 diabetes therapies.

In this report, entitled "MedPredict Thought Leader Insight & Analysis: T2 Diabetes," physician experts discuss the interplay between diabetes and cardiovascular disease.

"Recent changes to the American Diabetes Association guidelines highlight the diabetic's increased risk for coronary artery disease (CAD)," according to MedPredict's President Jeff Berk. "In light of these guidelines, our Panel provides insight into unmet needs and the endocrinologist's emerging therapeutic management strategies for diabetes, CAD, metabolic syndrome and nonalcoholic steatohepatitis (NASH)."

Also discussed:

-- Incretins will dominate new launches for HbA1c lowering drugs for the

next few years. The Panel discusses the significance of targeting

DPP4, DPP8 and DPP9, and compares this class with GLP-1 agonists.

Strengths and weaknesses of new monotherapies and combination

approaches are discussed.

-- These new orals and parenterals will put pressure on established

products, including metformin, sulfonylureas and TZDs. The Panel

offers insight into how each fits into the diabetes / CAD paradigm.

-- The Panel describes why Exubera has failed commercially, and

benchmarks next-generation insulins.

-- While still very early in development, the Panel shared key insights

about the future for inhibition of SGLT.

Key products mentioned in this report: metformin, Januvia/Janumet (sitagliptin; Merck), Byetta (exenatide; Lilly/Amylin), exenatide LAR (Lilly/Amylin/Alkermes), Symlin (Amylin), pramlintide + leptin (Amylin/Amgen), Galvus (vildagliptin; Novartis), alogliptin (Takeda), saxagliptin (BMS/AZ), Redona (denagliptin; GSK), liraglutide (Novo Nordisk), Boc5 (UC Riverside / Chinese Acad. Sci.), substituted quinoxalines (Pfizer/Novo Nordisk), Actos (pioglitazone; Takeda/Lilly), Avandia (rosiglitazone; GSK), Exubera (Nektar), AIR Insulin (Lilly/Alkermes), Technosphere (Mannkind), AERx (Novo Nordisk/Aradigm), Oral-lyn (Generex/Lilly), buccal insulin (GSK).

This report can be purchased by contacting MedPredict. Members of the media may request an interview.

About MedPredict

MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Virginia Tech Review Panel Calls For Reform of Mental Health Treatment Law
2. CryoCor Invited to Participate in FDA Advisory Panel Meeting on Atrial Fibrillation
3. Patient Safety Authority Board of Directors Names Infection Advisory Panel
4. Partners Rx Chief Pharmacy Officer, Richard Bullard on Panel Discussion at the Fall 2007 Managed Markets Summit (MMS) in Phoenix, AZ.
5. Billians HealthDATA GM Speaking on Dreamforce 07 Panel
6. FDA Panel Recommends Approval of SyntheMeds REPEL-CV(R) Adhesion Barrier for Pediatric Patients
7. Abaxis Announces New Waived Kidney Check Panel Exclusively for Imaging and Radiology Centers
8. Health Courts Critic to be Featured Speaker at Wyoming Patient Safety Panel
9. FDA Panel Mulls Ban on Kids Cold Medicines
10. FDA Panel Weighs Ban on Kids Cold Medicines
11. FDA Panel Recommends Ban on Cold Medicines for Kids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of ... its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his ... July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming ...
(Date:10/13/2017)... ... ... Apple Rehab Shelton Lakes , which specializes in the delivery of sub-acute ... of a disaster drill on October 3rd. , Apple Rehab participated with the Shelton ... well as the Connecticut Long Term Care Mutual Aid Plan (LTC-MAP). The LTC-MAP ...
(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare ... program management, will showcase a range of technology and learning solutions at the ... Convention and Expo to be held October 14–18, 2017 at the Mandalay Bay ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris F. ... AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking place ... the field of medical informatics, this prestigious award is presented to an individual whose ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... , and named its founder as Diplomat,s chief information ... Tennessee , will operate under Diplomat subsidiary Envoy ... for health care partners to include IT outsourcing, consulting, ... "In an interoperable world, technology delivers comprehensive insight and ...
(Date:10/2/2017)... Denmark , Oct. 2, 2017 The Rebound ... in the struggle to reverse the tide of prescription drug ... for regulating their medicine intake and stepping down their dosage ... set to launch in December 2017; the first 100,000 people ... Learn more at http://www.rebound-solution.com/ ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017  DarioHealth ... and big data solutions, today announced that its MyDario product is expected ... local TV listings for when The Dr. Oz Show airs in your ... The nine-time Emmy ... ...
Breaking Medicine Technology: